Abstract
VIRxSYS is developing VRX-496, a lentiviral HIV-based vector encoding anti-HIV antisense envelope sequences, as a potential gene therapy for HIV infection. In July 2003, VIRxSYS undertook the initial dosing of an HIV-positive patient in a phase I/IIa trial.
MeSH terms
-
AIDS Vaccines / adverse effects
-
AIDS Vaccines / chemical synthesis
-
AIDS Vaccines / pharmacology*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Contraindications
-
HIV Infections / prevention & control*
-
HIV-1 / immunology*
-
Structure-Activity Relationship